Immunosuppression & Transplant Nursing Guide 2026

⚕️ Medical Disclaimer: This content is for educational purposes only and is intended for licensed healthcare professionals. It does not constitute medical advice and should not replace clinical judgment, facility protocols, or physician orders. Always verify medications, doses, and procedures with your institution's guidelines.

Part of the ICU Emergencies Hub — browse every related guide in one place.

This article was created with AI assistance.

Transplant rejection types, immunosuppressive drug classes and toxicities, infection surveillance, graft-versus-host disease, and comprehensive post-transplant nursing management.

1. Types of Transplant Rejection

Type	Onset	Mechanism	Clinical Features	Treatment
Hyperacute	Minutes to hours after reperfusion	Preformed recipient antibodies against donor antigens (ABO incompatibility or pre-sensitized)	Immediate graft failure; organ becomes mottled, cyanotic on the table; fever, hypotension	No effective treatment — graft must be removed immediately. Prevention: careful crossmatch before transplant.
Acute (cellular)	Days to 3 months (can occur anytime)	T-cell mediated immune response against donor HLA antigens	Fever, graft tenderness and swelling, decreased organ function (rising Cr for kidney, rising LFTs for liver, rising BNP for heart)	High-dose IV corticosteroids (pulse methylprednisolone); anti-thymocyte globulin (ATG) for steroid-refractory
Chronic	Months to years	Slow immune-mediated damage; antibody + T-cell mediated; fibrosis	Slow progressive graft dysfunction; kidney: interstitial fibrosis; heart: cardiac allograft vasculopathy; lung: bronchiolitis obliterans syndrome (BOS)	Optimize immunosuppression; no cure — leads to eventual graft loss; may require re-transplantation

2. Signs of Acute Rejection by Organ

Organ	Signs of Rejection	Key Lab/Test
Kidney	Decreased UO, rising creatinine, graft tenderness/swelling, fluid retention, hypertension, fever	Rising serum creatinine; biopsy for confirmation; renal ultrasound
Liver	Jaundice, fatigue, fever, rising LFTs (AST/ALT/bilirubin/ALP)	LFTs; liver biopsy
Heart	Dyspnea, fatigue, decreased exercise tolerance, arrhythmias, signs of HF (edema, JVD)	Endomyocardial biopsy (gold standard); BNP; echo (decreased EF)
Lung	Dyspnea, decreased FEV1, cough, fever (early); BOS = progressive obstructive pattern	PFTs; bronchoscopy with BAL and biopsy
Pancreas/Islet	Hyperglycemia (rising blood glucose)	Fasting glucose; amylase/lipase if whole pancreas

3. Immunosuppressive Medications

Drug Class/Name	Mechanism	Key Toxicities	Monitoring
Tacrolimus (FK506, Prograf)	Calcineurin inhibitor — blocks IL-2 production → inhibits T-cell activation	Nephrotoxicity (most significant), neurotoxicity (tremors, headache, seizures), hypertension, hyperglycemia (PTDM — post-transplant diabetes mellitus), hyperkalemia, alopecia	Trough levels (goal varies by organ/time post-transplant, typically 8–12 ng/mL early); Cr; BMP (K+, glucose); daily BP
Cyclosporine (Sandimmune, Neoral)	Calcineurin inhibitor (same class as tacrolimus)	Nephrotoxicity, hypertension, hyperlipidemia, gingival hyperplasia, hirsutism, neurotoxicity	Trough or 2-hour levels; Cr; lipids; BP
Mycophenolate mofetil (CellCept)/Mycophenolate sodium (Myfortic)	Antimetabolite — inhibits purine synthesis → blocks lymphocyte proliferation	GI side effects (diarrhea, nausea, vomiting, abdominal cramps — major reason for dose reduction), myelosuppression (leukopenia, thrombocytopenia), teratogenic (NEVER in pregnancy — causes fetal malformations)	CBC with differential weekly-monthly; use effective contraception in women of childbearing age
Azathioprine (Imuran)	Antimetabolite — thiopurine; blocks DNA synthesis	Myelosuppression, hepatotoxicity, GI effects, increased malignancy risk	CBC; LFTs; avoid allopurinol (increases toxicity dramatically)
Corticosteroids (Prednisone)	Broad anti-inflammatory; suppresses multiple immune pathways	Infection risk, hyperglycemia, hypertension, osteoporosis, weight gain, Cushingoid appearance, mood changes, cataracts, avascular necrosis of femoral head, poor wound healing, adrenal suppression	Glucose; BP; bone density (DEXA); calcium/vitamin D supplementation; do not abruptly stop
Sirolimus/Everolimus (mTOR inhibitors)	Blocks mTOR → inhibits T-cell proliferation and cytokine signaling	Poor wound healing (avoid perioperatively), hyperlipidemia, mouth ulcers, myelosuppression, pneumonitis, edema	Trough levels; lipids; CBC; LFTs; hold perioperatively
Belatacept	Costimulation blocker — blocks T-cell activation signal	IV infusion only (monthly); increased risk of PTLD (post-transplant lymphoproliferative disorder) especially in EBV-seronegative recipients	EBV serostatus before starting; LFTs; signs of PTLD

4. Infection in the Immunosuppressed Patient

Immunosuppressed patients cannot mount a normal immune response — infections present ATYPICALLY:

Fever may be absent or blunted even with serious infection
WBC may be normal or only mildly elevated
Symptoms may be minimal until infection is severe
Low threshold to culture, image, and treat

Infection Timeline Post-Transplant

Time Period	Predominant Infections
First month	Donor-derived infections, surgical site infections, hospital-acquired infections (MRSA, C. diff, Candida, gram-negatives), UTI (Foley-related)
1–6 months (peak immunosuppression)	Opportunistic infections: CMV (most common), PCP (Pneumocystis jirovecii pneumonia), fungal (Aspergillus, Candida), Toxoplasma, EBV/PTLD, BK virus (kidney)
Beyond 6 months	Community-acquired infections similar to general population; chronic rejection → bronchiectasis/recurrent pneumonias (lung); reactivation of latent infections (TB, histoplasmosis)

CMV (Cytomegalovirus) — Most Important Post-Transplant Infection

Risk: Donor CMV+ / Recipient CMV- (highest risk)
Presentation: fever, malaise, leukopenia, organ involvement (esophagitis/colitis/pneumonitis/retinitis)
Prevention: valganciclovir prophylaxis × 3–6 months
Treatment: IV ganciclovir → oral valganciclovir; reduce immunosuppression if possible
Monitoring: CMV PCR levels

5. Graft-Versus-Host Disease (GVHD)

Occurs in BONE MARROW/STEM CELL transplants (not solid organ transplants — reversed situation).
The transplanted donor immune cells attack the recipient's tissues.

Acute GVHD (first 100 days): Skin rash (maculopapular, starts on palms/soles/ears), diarrhea (can be massive, watery, bloody), elevated LFTs/jaundice
Chronic GVHD (after 100 days): Skin changes (lichen planus-like, scleroderma-like), dry eyes/mouth, lung disease (BOS), joint contractures, cytopenias

Treatment: High-dose corticosteroids first-line; ruxolitinib for steroid-refractory
Prevention: tacrolimus + methotrexate; HLA matching; T-cell depletion

6. Post-Transplant Nursing Priorities

Infection control: strict hand hygiene; private room; neutropenic precautions if leukopenic; avoid fresh flowers, plants, and raw foods; limit visitor exposure
Medication adherence: never miss doses of immunosuppressants; missing doses = rejection risk; educate on importance
Rejection surveillance: daily weights; UO monitoring (kidney); daily creatinine; assess for organ-specific rejection signs
Sun protection: skin cancer risk is 65× higher in transplant patients; sunscreen, hats, long sleeves mandatory
Cancer screening: increased risk of lymphoma (PTLD), skin cancer, cervical cancer, anal cancer; regular screenings
Drug interactions: tacrolimus and cyclosporine have extensive drug interactions through CYP3A4 — azithromycin, fluconazole, diltiazem increase levels; rifampin dramatically DECREASES levels; always check interactions

NCLEX High-Yield: Transplant & Immunosuppression

Hyperacute rejection: within minutes to hours; preformed antibodies; graft removed immediately
Acute rejection: days to months; T-cell mediated; treat with high-dose steroids
Tacrolimus: nephrotoxicity + neurotoxicity (tremors); monitor trough levels
Mycophenolate: major side effect = GI disturbances (diarrhea); teratogenic — contraindicated in pregnancy
Corticosteroids: hyperglycemia, infection risk, poor wound healing, avascular necrosis of hip
CMV: most common opportunistic infection post-transplant; prophylaxis with valganciclovir
GVHD: bone marrow transplant only; donor cells attack recipient; skin/GI/liver triad
Immunosuppressed patients: fever may be absent; low threshold to suspect infection
Skin cancer risk: 65× higher in transplant patients; strict sun protection required
Sirolimus/everolimus: hold perioperatively (impairs wound healing)

Get the ICU Notebook

Free investing strategies built for nurses. One email per week, no fluff.

Yes, send it free

No spam. Unsubscribe any time.